Cellectis SA (CLLS)vsInsmed Inc (INSM)
CLLS
Cellectis SA
$3.23
-5.56%
HEALTHCARE · Cap: $335.97M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 635% more annual revenue ($606.42M vs $82.55M). INSM leads profitability with a -2.1% profit margin vs -42.8%. INSM earns a higher WallStSmart Score of 39/100 (F).
CLLS
Hold37
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 105.9% year-over-year
Reasonable price relative to book value
Strong operational efficiency at 21.6%
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -30.7% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CLLS
The strongest argument for CLLS centers on Revenue Growth, Price/Book, Operating Margin. Revenue growth of 105.9% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CLLS
The primary concerns for CLLS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CLLS profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
CLLS carries more volatility with a beta of 2.85 — expect wider price swings.
CLLS is growing revenue faster at 105.9% — sustainability is the question.
CLLS generates stronger free cash flow (-43M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cellectis SA
HEALTHCARE · BIOTECHNOLOGY · USA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?